A 5 year old Caucasian female was referred to the endocrine clinic for assessment of tall stature. She was born at 39 weeks gestation following conception by ovulation induction with FSH pump for maternal hypogonadotrophic hypogonadism. Her mother was also noted to have polycystic ovaries. The pregnancy was uneventful. Her birth weight was 2580 g (<10th centile), birth length 48 cm (10–50th centile), and head circumference 32.5 cm (10th centile). There were no neonatal problems. She was generally a well child with normal early developmental milestones. There was a family history of mild non-insulin dependent diabetes mellitus affecting her father and maternal grandmother, treated with diet alone.

Until the age of 2 she was growing along the 75th centile for height and weight, in keeping with her genetic potential (mid-parental height 170 cm, 75–90th percentile). However, between the ages of 2 and 3 her height had crossed from the 75th percentile to 12 cm above the 97th percentile.

On initial examination at age 5 years, she was non-dysmorphic and proportionate. Her height was 131.2 cm (standard deviation score (SDS) +5.2), weight 35.85 kg (SDS 5.4%) and head circumference 52.5 cm. She was normotensive (blood pressure 90/60 mm Hg) and full systems examination was normal. She has evidence of adrenarche with early pubic hair and increased IGFBP-3 of 7.2 mg/l (2.2–4.6). Her father, who has type 2 diabetes mellitus affecting her father and maternal grandmother, developed type 2 diabetes mellitus by WHO criteria (table 1). Her bone age remains 2 years 6 months advanced. At the age of 6 years 3 months she was noted to have early acanthosis nigricans affecting the axillae, which has progressed. She has no evidence of lipodystrophy. She has notably impaired social interaction skills, despite high average IQ, and a diagnosis of Asperger’s syndrome is being entertained.

Her mother has also had fasting studies which show normal insulin of 4 mU/l (1–25), IGF-1 22 nmol/l (12.1–35), IGFBP-3 3.9 mg/l (2–4), and ALS 284 nmol/l (60–280). She has evidence of adrenarche with early pubic hair and DHEAS of 1.2 µmol/l (0.1–1.5).

Her mother has also had fasting studies which show normal insulin of 4 mU/l (1–25), IGF-1 22 nmol/l (12.1–35), HbA1c 5.4% (4.4–6.4), and ALS 267 nmol/l (120–265), but an increased IGFBP-3 of 7.2 mg/l (2.2–4.6). Her father, who has...
type 2 diabetes mellitus, has raised fasting insulin (32 mU/l) but normal IGF-1 (18.1 nmol/l).

**IN VITRO STUDIES OF SERUM BIOACTIVITY**

The possibility of a bioactive but non-immunoreactive growth hormone protein was excluded by non-detectable concentrations of bioactive growth hormone (<2 ng/ml) in a bioassay specific for the human GH receptor. This bioassay is based on the proliferation of mouse proB cells expressing the human GH receptor, and specificity for GH is achieved by measuring proliferation in the presence and absence of a specific GH antagonist. Samples from the patient at age 5 years showed an increased level of non-GH receptor mediated proliferation, corresponding to 15 ng/ml GH equivalent activity. This is higher than we have seen in over a hundred clinical samples. Therefore while the GH antagonist displaceable bioactivity was less than 2 ng/ml, the non-GH receptor mediated proliferation was equivalent to 15 ng/ml. Neither our patient’s extremely high insulin concentrations nor her increased IGF-1 for chronological age were sufficient to explain such an increase in assay baseline. In separate experiments, exposing the proB cells to an insulin concentration similar to that in the patient’s serum produced no stimulation. Using an insulin concentration six times that of our patient, the stimulation was only equivalent to 0.3 ng/ml hGH. We tentatively conclude that the patient is producing a growth promoting factor, other than insulin, IGF-1, or prolactin, which could account for her clinical state.

**DISCUSSION**

Our patient presented with clinical features and raised IGF-1 and IGFBP-3, suggesting a diagnosis of pituitary gigantism. However, there was no evidence of growth hormone excess; instead severe insulin resistance in the absence of obesity was revealed by the oral glucose tolerance test. There is a group of rare disorders with generalised or partial absence of subcutaneous fat (lipodystrophy), hyperinsulinaemia with insulin resistance, overgrowth and acromegaloideism, hyperlipidaemia, and non-ketotic diabetes mellitus. However, as loss of subcutaneous fat and hyperlipidaemia are early manifestations, our patient does not fit into this spectrum of disorders.

Our patient may represent a childhood variant of previously reported “insulin mediated pseudoacromegaly”, of which there have been a few reports in the adult endocrine literature. Pseudoacromegaly or acromegaloideism is a rare disorder characterised by overgrowth and acromegalic changes without excessive growth hormone or IGF-1 and without pituitary abnormality. Flier and colleagues reported an adult case similar to ours, except that his patient had normal IGF-1 concentrations (measured at age 19). Over time his patient developed acral enlargement, prognathism, wide spacing of the teeth, severe acanthosis nigricans, and notable enlargement of the tongue and ears—that is, features of acromegaly but without growth hormone excess. Our patient, by age 7 years, has not developed acral changes or coarsening of facial features. This may develop in time, by analogy with the situation in growth hormone excess in which a patient may develop acromegaly or pituitary gigantism depending on the timing of growth hormone hypersecretion in relation to epiphyseal fusion.

Flier and colleagues found a dissociation between the metabolic and mitogenic actions of insulin in pseudoacromegaly. While the insulin receptor sequence and expression are normal, insulin stimulated phosphoinositide 3-kinase activity is notably reduced in some patients with pseudoacromegaly.

---

**Table 1** Oral glucose tolerance test results, age 5 and age 7

<table>
<thead>
<tr>
<th></th>
<th>Age 5</th>
<th></th>
<th>Age 7</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Fasting</td>
<td>120 min</td>
<td>Fasting</td>
<td>120 min</td>
</tr>
<tr>
<td>Glucose [mmol/l]</td>
<td>4.2</td>
<td>9.3</td>
<td>4.4</td>
<td>12.4</td>
</tr>
<tr>
<td>Insulin [mU/l]</td>
<td>53</td>
<td>1588</td>
<td>65</td>
<td>3834</td>
</tr>
<tr>
<td>GH [mU/l]</td>
<td>&lt;0.1</td>
<td>&lt;0.1</td>
<td>&lt;0.1</td>
<td>&lt;0.1</td>
</tr>
<tr>
<td>IGFBP-1 [ng/ml]</td>
<td>18</td>
<td>6</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

Figure 1  Patient’s height (A) and weight (B) data plotted for age (centiles from CDC NCHS data 2000).
There are no previous reports of paediatric “pseudoacromegaly” or “pseudogigantism”. Our patient’s raised growth markers at age 5 could be a feature early in the disorder. Alternatively, while IGF-1 of 36 nmol/l is notably increased for a child age 5 years (reference range 4.7–22), it is only mildly increased for her corresponding bone age of 7.5 years (reference range 12.6–35). Nevertheless the IGFBP-3 and ALS concentrations were initially raised, even when normalised for bone age. These later became normal, which makes autonomous activation of the IGF axis unlikely.

Our patient has postnatal overgrowth associated with severe hyperinsulinism progressing to type 2 diabetes mellitus. She also has increased bioactivity in a cell proliferation assay which is evidently not a result of increased insulin, IGF-1, or prolactin. This suggests the presence of another circulating growth promoting factor. Such a factor has been previously proposed to explain the syndrome of “growth without insulin”. Our patient’s raised growth hormone (GH) seen in some children with panhypopituitarism.

Our patient has postnatal overgrowth associated with severe hyperinsulinism progressing to type 2 diabetes mellitus. She also has increased bioactivity in a cell proliferation assay which is evidently not a result of increased insulin, IGF-1, or prolactin. This suggests the presence of another circulating growth promoting factor. Such a factor has been previously proposed to explain the syndrome of “growth without insulin”. Our patient’s raised growth hormone (GH) seen in some children with panhypopituitarism.

**Authors’ affiliations**

S Srinivasan, C F Verge, Sydney Children’s Hospital, Sydney, Australia

M J Waters, J E Rowland, Department of Physiology and Pharmacology, University of Queensland, Brisbane, Australia

R C Baxter, Kaling Institute, Royal North Shore Hospital, Sydney, Australia

Correspondence to: Dr C F Verge, Department of Endocrinology, Sydney Children’s Hospital, High Street, Randwick, NSW 2031, Australia; vergec@sesahs.nsw.gov.au

Accepted 28 August 2002

**REFERENCES**


**Preventable blindness in Africa**

It has been estimated that some 1.4 million children around the world are blind and about three quarters of them live in Asia or Africa. Much of this blindness could be prevented or treated and a report from Nigeria (IR Ezegwui and colleagues. *Br J Ophthalmol* 2003;87:20–23) well illustrates this point.

In southeastern Nigeria there are three schools for blind pupils. Of 162 pupils, 142 were examined and two were excluded from the study because they were not blind. The rest were either blind (136 pupils) or had severe visual impairment (4). Six functionally blind pupils had significant vision when supplied with appropriate lenses. The most common cause of blindness was cataract (33, 24%). Thirty pupils (21%) had disease of the whole globe, of whom 17 had phthisis bulb (a soft and shrunken eye usually following infection or trauma). The other 13 had anophthalmos, microphthalmos, or disorganised globe. Corneal scarring was the cause of visual loss in 30 pupils (21%) and was attributed to measles in 26. The contribution of vitamin A deficiency was not assessed. Glaucoma or buphthalmos were the cause in 13 (9%). Ten cases (7%) were thought to have been the result of using traditional eye medications. For 54 pupils (39%) their blindness had resulted from factors active in childhood, 21 (15%) were considered hereditary, 11 (8%) from intrauterine causes, and for 54 (39%) the timing of the insult was unknown. In all, 91 pupils (65%) were blind from causes considered preventable (such as measles) or treatable (such as cataract).

Much childhood blindness in developing countries can be avoided. The causes of blindness vary between and within countries and local data are important in determining approaches to prevention and treatment.
Hyperinsulinism and overgrowth without obesity

S Srinivasan, M J Waters, J E Rowland, R C Baxter and C F Verge

Arch Dis Child 2003 88: 332-334
doi: 10.1136/adc.88.4.332

Updated information and services can be found at:
http://adc.bmj.com/content/88/4/332

These include:

References
This article cites 6 articles, 0 of which you can access for free at:
http://adc.bmj.com/content/88/4/332#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Drugs: endocrine system (120)
- Diabetes (339)
- Metabolic disorders (761)
- Dermatology (377)
- Drugs: CNS (not psychiatric) (497)
- Health education (555)
- Health promotion (611)
- Obesity (nutrition) (325)
- Obesity (public health) (325)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/